| | | Per MofA, it does not looks that RO6875281 will be combined with PD1(L1) as synergy combo regime, so general thesis of direct competition is not valid, IMO.
Second, as I mentioned early at SI, it is all about SYNERGY, and can 214 help enhance/extend PD1 benefit? We are entering period when is obvious that anti-PD1 therapy should go pass 2Y active treatment, so safe and complementary IO candidate that can add to this general view (without been too much expensive...which 214 should not be???!!!) will be winner, long term.
I can not say that 214 is sure thing, but that it is complete failure and worth ZERO, is even more exaggerated statement from SHORT.
One sure thing about second IO is Yervoy. But one need to develop more safe (even more potent) anti-CTLA4 drug. |
|
